Latest Partnerships News

Industrial Minerals Ltd has announced a maiden JORC Inferred Mineral Resource Estimate of 6.2 million tonnes at 98% silica for its Pippingarra Quarry Project, signalling a significant step forward in supplying high-value quartz to advanced technology markets.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.

333D Ltd reports continued revenue growth in digital asset management and unveils a pioneering blockchain solution for MRI data storage, reinforcing its foothold in digital healthcare.

Oakridge International reports solid growth in healthcare technology revenues and product development progress, while navigating a potential legal claim from Teko International.

Australian Rare Earths Limited (ASX – AR3) has made significant strides in advancing its Koppamurra Rare Earths Project, securing pilot-scale processing at ANSTO’s new facility and raising $6 million post-quarter to fund development. Concurrently, promising uranium targets have been identified at its Overland Project.

State Gas Limited has independently certified a maiden 2P gas reserve of 30.2 PJ at its Rolleston West Project, underpinning plans for a 10TJ/day gas development. The company also raised $3.2 million through convertible notes to accelerate pre-development activities.

Aspire Mining has taken a major step forward in developing its Ovoot Coking Coal Project by signing a $69.9 million EPC contract and gaining government backing for a key highway project, positioning the company for first coal exports by late 2027.

Eminence Minerals reports strong near-surface rare earth results in Brazil and advances a judicial review over heritage site decisions in Western Australia, while appointing new leadership to drive growth.

Alchemy Resources reported strong exploration progress in lithium, iron ore, and base metals across Western Australia and New South Wales, highlighted by promising drill results and strategic joint ventures.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.

Pathkey.AI has completed a strategic review, bolstered its leadership team, and secured $3.5 million in funding to accelerate growth and broaden its AI platform's applications beyond clinical trials.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.